CATALYSTYahoo Finance • 7h ago
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Why PODD Stock slipped -1.85% Today — RQD Quant Desk Flash
$149.68 -1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $149.54
Insulet Corporation (PODD) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (72% profit margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $10.58B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PODD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PODD compare to GMED and BAX in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PODD?
▼
Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $149.55 (-0.09%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 13.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+6.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PODD)Realized 20D OHLCV Swing Band: ±6.2%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY PODD SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($377.7M FCF) & 71.6% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)
Altman Z-Score 5.72 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)
Macro rate sensitivity & RSI-14 (66) create a -11 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$138.13+3.3% Next Q
65
Q2 (-2Q)Grade B-$142.64+5% Next Q
68
Q3 (-1Q)Grade B$149.83-0.1% Next Q
70
CurrentGrade B$149.68+7.1% Hist 90D α
73
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PODD Bull Thesis Could Fail
Even with a 73/100 (B) score, PODD faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($141.14) or 200D SMA ($177.45) invalidates the momentum regime and cuts Target Base ($159.78) toward Bear Floor ($122.74).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PODD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PODD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PODD Stock slipped -1.85% Today — RQD Quant Desk Flash
Insulet Corporation (PODD) slipped -1.85% to $149.68, trading at 10% of its 52-week range ($126.4 – $354.88). High-quality cash engine (72% profit margin, 20% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 10% of its 52-week range ($126.4 – $354.88) with RSI-14 at 66 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.2% around $149.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 71.6% gross margin and $377.7M annual free cash flow.
Live PODD Headlines & Catalysts
MARKET WIREStock Titan • 10h ago
Insulet (PODD) CFO Flavia Pease has 1,882 shares withheld for vesting taxes at $130.79 each.Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 13h ago
Insulet's Quarterly Earnings Preview: What You Need to KnowYahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
CATALYSTQuiver Quantitative • 16h ago
Insulet Stock Gains as Traders Weigh Bullish Analyst Stance Against a Depressed Share Price | PODD Stock NewsQuiver Quantitative report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 19h ago
Insulet Corporation (PODD) Stock ForecastsYahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 22h ago
BlackRock reports a passive Insulet (PODD) stake and sole voting power over 5.09M shares.Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
PODD Q2 2026 Earnings: EPS Beats Estimates by 12.2%, Shares Rise 2.15% - Earnings Acceleration Pickshttps://www.dars.gov.et/ report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREopenPR.com • 1d ago
Investigation ALERT: Long-Term Investors who hold sharesopenPR.com report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 6d ago
S&P 500 Postmarket Decliners After Tuesday's CloseS&P 500 postmarket decliners after Tuesday's close included CoStar Group, NXP Semiconductors, Robinhood, Teradyne and Seagate.
MARKET WIREYahoo • 7d ago
Insulet (PODD) Could Be 11% Undervalued On Omnipod Discover LaunchOmnipod Discover launch puts Insulet’s data platform in focus Insulet (PODD) has rolled out Omnipod Discover nationwide in the US, extending a web-based data platform that earlier limited-release users and healthcare pro
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PODD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PODD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.67%▲ ASCENDING TRIANGLE
2026-11-02O $148.9H $152.5L $148.9C $149.7VOL 1.30M
RES: $154.9SUP: $128.9SMA50: $141.1SMA200: $177.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PODD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
32.2%/yr Implied 5Y Growth
vs. +30.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PODD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PODD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PODD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PODD)
Health Care Rank #57 of 1016
⚔️ GMED vs PODD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PODD vs. GMED, BAX, PEN, SOLV)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Insulet Corporation (PODD) ranks #57 by composite RQD confidence (73/100, grade B) and #106 by equity capitalization ($10.58B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PODD
ACTIVE
Insulet Corporation | B | 73/100 | 42.8x | 71.6% | 20.4% | -1.85% | $10.58B | Benchmark Subject |
| GMED Globus Medical Inc. | B | 72/100 | 20.7x | 67.4% | 8.7% | -5.86% | $11.13B | /gmed-vs-podd → |
| BAX Baxter International Inc. | D | 51/100 | — | 30.1% | -2.4% | -2.13% | $12.15B | /bax-vs-podd → |
| PEN Penumbra Inc. | D+ | 57/100 | 71.4x | 67.1% | 10.6% | -0.94% | $12.68B | /pen-vs-podd → |
| SOLV Solventum Corporation | D | 45/100 | 9.1x | 53.5% | 18.7% | -2.67% | $14.22B | /solv-vs-podd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001145197In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insulet Corporation (PODD) reported GAAP revenue of $2.71B (+30.7% vs. FY2024 revenue of $2.07B , and +59.6% cumulative change since FY2023) , GAAP net income of $247.1M, operating cash flow of $569.3M, and free cash flow of $377.7M (+23.7% YoY). On the balance sheet, PODD closed FY2025 with $3.19B in total assets against $753.8M in total debt (Altman Z-Score: 5.72, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.71B | $247.1M | $569.3M | $377.7M | $3.19B | $753.8M |
| FY2024 (FY) | 2024-12-31 | $2.07B | $418.3M | $430.2M | $305.3M | $3.09B | $844.2M |
| FY2023 (FY) | 2023-12-31 | $1.70B | $206.3M | $145.7M | $69.3M | $5.82B | $1.36B |
3. PODD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.
How does PODD compare to GMED and BAX in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PODD?
Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PODD trading relative to its 50-day, 200-day, and 52-week technical levels?
PODD last traded at $149.68 (-1.85% on volume of 1,090,433 shares), positioning the stock +6.05% above its 50-day simple moving average ($141.14) and -15.65% below its 200-day simple moving average ($177.45). Across its 52-week range of $126.40 to $354.88, PODD sits at the 10.2% percentile with a 14-day RSI of 66.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.2% ($140.40 to $158.96).
PODD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PODD stock moving today?
Why PODD Stock slipped -1.85% Today — RQD Quant Desk Flash. High-quality cash engine (72% profit margin, 20% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 73/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PODD — Insulet Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:22Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PODD scores 73 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine 19/20 (ROIC 20.4%; FCF yield 3.57%), Whale 13F Flow 11/20 (institutional accumulation and options positioning), Insider Conviction 16/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 0.99; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 5.72; Piotroski F 8/9; Debt/Equity 0.46).
The strongest pillar is the cash engine, which indicates the rating's fundamental case rests mainly on returns on invested capital and free-cash-flow generation rather than on valuation. The forensic balance-sheet pillar is also strong. The weakest pillar is macro regime fit, where the near-market beta suggests the stock tracks broader market movement rather than diverging from it. Whale flow is moderate. Upside drivers in this framework are continued cash generation and balance-sheet strength; valuation tradeoffs are visible in the elevated trailing P/E relative to the forward P/E, and the 3.57% FCF yield should be weighed against those multiples. This is an analytical summary of the rating's components, not personalized financial advice.
Snapshot
Business
Insulet Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the company profile. Not available in source data for specific products, customers, or revenue-generation detail. The source data reports gross margin of 71.6%, operating margin of 17.5%, and net margin of 9.1% per the market data section.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $2708.1M | $473.8M | $247.1M | N/A | $377.7M | N/A | $753.8M |
| FY 2024 | $2071.6M | $308.9M | $418.3M | N/A | $305.3M | N/A | $844.2M |
| FY 2023 | $1697.1M | $220.1M | $206.3M | N/A | $69.3M | N/A | $1361.2M |
Reported revenue rose across the three periods, from $1697.1M in FY 2023 to $2708.1M in FY 2025, and debt declined from $1361.2M to $753.8M over the same span. Net income was $418.3M in FY 2024 and $247.1M in FY 2025. Per the market data, ROIC is 20.4% and net margin is 9.1%. Per the Roarable RQD forensic pillar, the Altman Z-Score is 5.72, the Piotroski F-Score is 8/9, and Debt/Equity is 0.46, which together describe a balance sheet the source data characterizes as strong. Cash balances are not available in source data.
Open Questions
- What are the reported cash balances, since the financials section lists cash as N/A for every period?
- What are the reported EPS figures, since the financials section lists EPS as N/A for every period?
- What is the analyst consensus rating and price target, given that analyst data is absent?
- What is the reported supply-chain exposure, given the butterfly graph shows no links?
- How do the 52-week high and low ($354.88 and $126.4) relate to the drivers behind the current price of $152.5?
PODD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Insulet Corporation (PODD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 7h ago
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 10h ago
Insulet (PODD) CFO Flavia Pease has 1,882 shares withheld for vesting taxes at $130.79 each. Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 13h ago
Insulet's Quarterly Earnings Preview: What You Need to Know Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Quiver Quantitative • 16h ago
Insulet Stock Gains as Traders Weigh Bullish Analyst Stance Against a Depressed Share Price | PODD Stock News Quiver Quantitative report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 19h ago
Insulet Corporation (PODD) Stock Forecasts Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
BlackRock reports a passive Insulet (PODD) stake and sole voting power over 5.09M shares. Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
PODD Q2 2026 Earnings: EPS Beats Estimates by 12.2%, Shares Rise 2.15% - Earnings Acceleration Picks https://www.dars.gov.et/ report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE openPR.com • 1d ago
Investigation ALERT: Long-Term Investors who hold shares openPR.com report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PODD Bull vs. Bear Conversation Board — What's Your Call at $149.68?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PODD 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $179.95 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PODD (B • RQD 73/100) a Buy at $152.50?
Welcome to the PODD (Insulet Corporation) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (20.4% ROIC), while bears focus on valuation multiple compression (42.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $125.05 (-18.0%)
Spot @ $152.50 Pump the brakes on PODD — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PODD, but look at what you are paying: 42.8x trailing P/E with 71.6% gross margins. Unless Insulet Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $176.90 (+16.0%)
Spot @ $152.50 PODD cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PODD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $152.50 (52-wk range $126.40 - $354.88), any beat on forward guidance forces shorts and underweight funds to chase.